

In The Claims

1-12. (cancelled)

13. (currently amended) A method of treating a solid tumor, comprising administering an effective amount of ~~[[camptothecin, or a camptothecin derivative]]~~ CPT-11 as a first agent, in combination with administration of an effective amount of a topoisomerase II inhibitor as a second agent, wherein the agents are administered simultaneously, semi-simultaneously, or separately, and wherein said first and second agents provide a therapeutic synergy superior to each of the agents used alone at its optimum dose in the treatment of said tumor, and wherein said agents are administered intravenously or orally.

14. (currently amended) The method according to Claim 13, wherein ~~[[the camptothecin derivative is CPT-11, and]]~~ the topoisomerase II inhibitor is an anthracycline antibiotic.

15. (original) The method according to Claim 14, wherein said antibiotic is doxorubicin.

16. (original) The method according to Claim 14, wherein said antibiotic is daunorubicin.

17. (currently amended) The method according to Claim 13, wherein ~~[[the camptothecin derivative is CPT-11, and]]~~ the topoisomerase II inhibitor is an epipodophyllotoxin.

18. (original) The method according to Claim 17, wherein said epipodophyllotoxin is etoposide.

19. (original) The method according to Claim 17, wherein said epipodophyllotoxin is teniposide.

20. (currently amended) The method according to any one of Claims 13-19, wherein the CPT-11 ~~[[camptothecin derivative]]~~ is administered orally.

21. (cancelled) ~~The method according to Claim 13, wherein the first agent is CPT-11.~~

22. (previously presented) The method according to Claim 14, wherein the anthracycline antibiotic is danorubicin, doxorubicin, annamycin, epirubicin, mitomycin, bleomycin, idamycin or cororubicin.

23. (previously presented) The method according to Claim 13, wherein the solid tumor is a mammary adenocarcinoma.

24. (previously presented) The method according to Claim 13, wherein the solid tumor is pancreatic ductal adenocarcinoma.

25. (currently amended) The method according to Claim ~~[[24]]~~ 13 wherein the CPT-11 is administered orally or intravenously.

26. (previously presented) The method according to Claim 13, wherein the second agent is administered intravenously.

27. (currently amended) The method according to Claim 13, wherein the ~~[[first agent is]]~~ CPT-11 ~~[[and]]~~ is administered orally or intravenously and the second agent is administered intravenously.